Y Mabs Therapeutics Stock Investor Sentiment

YMAB Stock  USD 9.77  0.24  2.40%   
About 67% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Y MAbs Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at simplywall.st         
Were Not Worried About Y-mAbs Therapeutics Cash Burn
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
Y-mAbs Therapeutics Shares Gap Up to 12.07 - Defense World
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Were Not Worried About Y-mAbs Therapeutics Cash Burn
Yahoo News
over three months ago at www.macroaxis.com         
Acquisition by Pfreundschuh Peter P. of 46000 shares of Y MAbs subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Y-mAbs Therapeutics initiated with a Buy at JonesResearch - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Y-MABS THERAPEUTICS, INC. SHAREHOLDER CLASS ACTION ALERT Bernstein Liebhard LLP Reminds Investors of...
Google News at Macroaxis
over three months ago at news.google.com         
Principal Financial Group Inc. Sells 1100 Shares of Y-mAbs Therapeutics, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
How to Take Advantage of moves in - Stock Traders Daily
Google News at Macroaxis
over three months ago at news.google.com         
Y-mAbs Therapeutics Inc. filed SEC Form 8-K Leadership Update, Regulation FD Disclosure, Financial S...
Google News at Macroaxis
over three months ago at seekingalpha.com         
Y-mAbs names Peter Pfreundschuh as CFO
seekingalpha News
over three months ago at news.google.com         
Insider Trading
Google News at Macroaxis
over three months ago at news.google.com         
Y-mAbs Therapeutics, Inc. Receives Consensus Recommendation of Hold from Analysts - Defense World
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Susan Smith of 35700 shares of Y MAbs at 9.83 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Technical Data - Stock Traders Daily
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 00 shares by Thomas Gad of Y MAbs at 16.44 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Y MAbs that are available to investors today. That information is available publicly through YMAB media outlets and privately through word of mouth or via YMAB internal channels. However, regardless of the origin, that massive amount of YMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Y MAbs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Y MAbs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Y MAbs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Y MAbs alpha.

Y MAbs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 22831 shares by Thomas Gad of Y MAbs at 4.38 subject to Rule 16b-3
09/19/2024
2
Insider Trading
09/27/2024
3
Disposition of 722 shares by Ber Gerard of Y MAbs at 12.0 subject to Rule 16b-3
10/04/2024
4
Vanguard Group Incs Strategic Acquisition in Y-mAbs Therapeutics Inc
11/05/2024
5
Y-mAbs Therapeutics Inc Reports Q3 2024 Revenue of 18.5 Million, EPS of 0. ...
11/08/2024
6
BMO cuts YMAB stock target on Q3 revenue miss
11/11/2024
7
Y-mAbs Therapeutics Trading Down 8.5 percent Heres What Happened
11/15/2024
8
Y-mAbs Therapeutics, Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat
11/21/2024
9
Y-mAbs to Participate at Citis 2024 Global Healthcare Conference
11/27/2024
10
Acquisition by Wg Biotech Aps of 30671 shares of Y MAbs at 5.8125 subject to Rule 16b-3
12/06/2024
11
Y-mAbs Therapeutics, Inc. Shares Sold by Point72 Asset Management L.P. - MarketBeat
12/11/2024

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Stocks Directory
Find actively traded stocks across global markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments